These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1921784)

  • 1. Sublingual apomorphine solution in Parkinson's disease.
    Panegyres PK; Graham SJ; Williams BK; Higgins BM; Morris JG
    Med J Aust; 1991 Sep; 155(6):371-4. PubMed ID: 1921784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Barbato L; Monge A; Nordera G; Ruggieri S
    Clin Neuropharmacol; 2003; 26(3):151-5. PubMed ID: 12782918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
    Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
    van Laar T; Jansen EN; Essink AW; Neef C; Oosterloo S; Roos RA
    Clin Neurol Neurosurg; 1993 Sep; 95(3):231-5. PubMed ID: 8242966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomorphine in the diagnosis and treatment of parkinsonian tremor.
    Hughes AJ; Lees AJ; Stern GM
    Clin Neuropharmacol; 1990 Aug; 13(4):312-7. PubMed ID: 2208183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
    Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
    Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption of apomorphine by various routes in parkinsonism.
    Gancher ST; Nutt JG; Woodward WR
    Mov Disord; 1991; 6(3):212-6. PubMed ID: 1922125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.